Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...

Researchers from Leiden University, University of York, University of Barcelona/IQTCUB/ICREA and The Francis Crick Institute ...

WEHI researchers have led a major global effort to create the first authoritative atlas for a class of enzymes that regulate almost every cellular process in the human body. Published in Cell, the ...

A newly published study reports that APC-deficient cancer cells may depend on a single metabolic enzyme for survival, ...

A surprising new study reveals that blocking a supposedly protective enzyme, Caspase-2, could actually backfire—raising the risk of chronic liver damage and cancer over time. Researchers found that ...

Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...

Squid ink is a melanin-rich marine secretion with promising antioxidant, antimicrobial, and other bioactive properties, but most evidence comes from laboratory and preclinical studies rather than ...

PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show ...

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

The oral molecular glue degrader aims to overcome resistance to standard ALK tyrosine kinase inhibitor therapies.